Abstract
Cyclosporin A (CSA) has transformed clinical transplantation, both in term of success and of quality-of-life of the patient. Studies aimed to unfold the site of CSA action have shown that this molecule binds to cytosolic proteins of the cyclophilin family. CSA:cyclophilin complexes have a high affinity for calcineurin, a key enzyme in T-cell activation. By blocking the calcineurin activity, CSA prevents the induction of genes encoding for cytokines and their receptors. Thus, humoral and cellular immune responses are abolished, this resulting in the successful graft acceptance. Disappointingly, CSA and the other molecules as FK506, sharing the capacity to inhibit calcineurin, should be administered for all patient life, as tolerance to alloantigens is not achieved by these molecules. The long term utilization of this class of immunosuppressors increases the incidence of different tumors. The finding that CSA does not interfere with various biochemical pathways has prompted different groups to analyze a possible effect of CSA on molecules that might be involved in different functions of the immune response and / or in tumorogenesis. A new picture of CSA mode of action is emerging in which the immunosuppressor prevents the transcription of a group of genes, concomitantly inducing the transcription of another set. Here, we review the data and discuss the consequences of these new findings in term of T-cell activation mechanisms.
Keywords: Cyclosporin, immunosuppressors, calcineurin, cytosolic proteins
Mini-Reviews in Medicinal Chemistry
Title: New Aspects of Cyclosporin A Mode of Action: from Gene Silencing to Gene Up-Regulation
Volume: 3 Issue: 3
Author(s): Laurent Mascarell and Paolo Truffa-Bachi
Affiliation:
Keywords: Cyclosporin, immunosuppressors, calcineurin, cytosolic proteins
Abstract: Cyclosporin A (CSA) has transformed clinical transplantation, both in term of success and of quality-of-life of the patient. Studies aimed to unfold the site of CSA action have shown that this molecule binds to cytosolic proteins of the cyclophilin family. CSA:cyclophilin complexes have a high affinity for calcineurin, a key enzyme in T-cell activation. By blocking the calcineurin activity, CSA prevents the induction of genes encoding for cytokines and their receptors. Thus, humoral and cellular immune responses are abolished, this resulting in the successful graft acceptance. Disappointingly, CSA and the other molecules as FK506, sharing the capacity to inhibit calcineurin, should be administered for all patient life, as tolerance to alloantigens is not achieved by these molecules. The long term utilization of this class of immunosuppressors increases the incidence of different tumors. The finding that CSA does not interfere with various biochemical pathways has prompted different groups to analyze a possible effect of CSA on molecules that might be involved in different functions of the immune response and / or in tumorogenesis. A new picture of CSA mode of action is emerging in which the immunosuppressor prevents the transcription of a group of genes, concomitantly inducing the transcription of another set. Here, we review the data and discuss the consequences of these new findings in term of T-cell activation mechanisms.
Export Options
About this article
Cite this article as:
Mascarell Laurent and Truffa-Bachi Paolo, New Aspects of Cyclosporin A Mode of Action: from Gene Silencing to Gene Up-Regulation, Mini-Reviews in Medicinal Chemistry 2003; 3 (3) . https://dx.doi.org/10.2174/1389557033488150
DOI https://dx.doi.org/10.2174/1389557033488150 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Mitochondria as a Therapeutic Target in Metabolic Disorders
Mitochondria are the primary site of adenosine triphosphate (ATP) production in mammalian cells. Moreover, these organelles are an important source of reactive oxygen and nitrogen species in virtually any nucleated cell type. The modulation of a myriad of cellular signaling pathways depends on the mitochondrial physiology. Mitochondrial dysfunction is observed ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Understanding Autophagy in Cell Death Control
Current Pharmaceutical Design Recent Patents in Circulating Cell-Free Tumor DNA as Biomarker in Cancer
Recent Patents on Biomarkers Targeting Heat Shock Protein 90 for Malaria
Mini-Reviews in Medicinal Chemistry Potential Gene Therapy Strategies for Cancer Stem Cells
Current Gene Therapy Inhibition of HIV-1 Entry into Cells
Recent Patents on Anti-Infective Drug Discovery High-throughput Screening Identifies Small Molecule Inhibitors of Molecular Chaperones
Current Pharmaceutical Design Application of Serial Analysis of Gene Expression in Cancer Research
Current Pharmaceutical Biotechnology Paris polyphylla: Chemical and Biological Prospectives
Anti-Cancer Agents in Medicinal Chemistry 1-O-Octadecyl-2-O-Methylglycero-3-phosphocholine (Edelfosine) and Cancer Cell Invasion: A Short Review
Anti-Cancer Agents in Medicinal Chemistry Mesenchymal Cells in the Treatment of Spinal Cord Injury: Current & Future Perspectives
Current Stem Cell Research & Therapy Glioblastoma Tumor Initiating Cells: Therapeutic Strategies Targeting Apoptosis and MicroRNA Pathways
Current Molecular Medicine Astrocytic α7 Nicotinic Receptor Activation Inhibits Amyloid-β Aggregation by Upregulating Endogenous αB-crystallin through the PI3K/Akt Signaling Pathway
Current Alzheimer Research Bridging the Gap Between Chemistry and Biotechnology - Large Molecules with Potential, How Could Biotechnology Complement Chemistry?
Current Organic Chemistry Recent Advances in Heterocyclic Tubulin Inhibitors Targeting the Colchicine Binding Site
Anti-Cancer Agents in Medicinal Chemistry The Role of Histone Demethylase GASC1 in Cancer and its Therapeutic Potential
Current Cancer Therapy Reviews Neutrophil Extracellular Traps as a Drug Target to Counteract Chronic and Acute Inflammation
Current Pharmaceutical Biotechnology Cancer and the Endogenous “Pineal Clock”: A Means of Early Diagnosis and Successful Treatment as Well as Prevention of Cancers
Current Aging Science HDAC as a Therapeutic Target for Treatment of Endometrial Cancers
Current Pharmaceutical Design Evaluation of Drug Targeting Strategies and Liposomal Trafficking
Current Pharmaceutical Design S100A8/A9 as a Pro-inflammatory Cytokine in Obstructive Airway Disease Via the Multi-Ligand Receptor, RAGE
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry